NGM logo

NGM Biopharmaceuticals (NGM) Stock

Profile

Full Name:

NGM Biopharmaceuticals, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

04 April 2019

Indexes:

Not included

Description:

NGM Biopharmaceuticals, Inc. is a biopharmaceutical company that works with clinical stages of diseases. They are involved in the development of new therapeutic agents for the treatment of cardiovascular-metabolic, liver, oncological, and ophthalmological diseases. NGM Biopharmaceuticals, Inc. was registered in 2007, and its headquarters are located in South San Francisco, California.

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

May 03, 2024

Recent annual earnings:

Mar 11, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

12 Mar '24 Raymond James
Market Perform
28 Feb '24 TD Cowen
Market Perform
22 Nov '23 B. Riley Securities
Buy
03 May '23 Citigroup
Buy
30 Mar '23 B. Riley Securities
Buy
04 Nov '22 Raymond James
Outperform
18 Oct '22 Raymond James
Outperform
18 Oct '22 Goldman Sachs
Neutral
18 Oct '22 Cowen & Co.
Outperform
17 Oct '22 Piper Sandler
Neutral

Screeners with NGM included

No data

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Similar stocks

NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting
NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting
NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting
NGM
GlobeNewsWire19 March 2024

SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that two abstracts highlighting clinical data from the ongoing Phase 1/2 clinical trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, have been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting, being held April 5-10, 2024 in San Diego, CA.

NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Lags Revenue Estimates
NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Lags Revenue Estimates
NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Lags Revenue Estimates
NGM
Zacks Investment Research11 March 2024

NGM Biopharmaceuticals (NGM) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.45 per share a year ago.

Why NGM Biopharmaceuticals (NGM) Might Surprise This Earnings Season
Why NGM Biopharmaceuticals (NGM) Might Surprise This Earnings Season
Why NGM Biopharmaceuticals (NGM) Might Surprise This Earnings Season
NGM
Zacks Investment Research07 March 2024

NGM Biopharmaceuticals (NGM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

NGM Biopharmaceuticals (NGM) Reports Q3 Loss, Misses Revenue Estimates
NGM Biopharmaceuticals (NGM) Reports Q3 Loss, Misses Revenue Estimates
NGM Biopharmaceuticals (NGM) Reports Q3 Loss, Misses Revenue Estimates
NGM
Zacks Investment Research02 November 2023

NGM Biopharmaceuticals (NGM) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.59 per share a year ago.

NGM Biopharmaceuticals (NGM) Reports Q2 Loss, Misses Revenue Estimates
NGM Biopharmaceuticals (NGM) Reports Q2 Loss, Misses Revenue Estimates
NGM Biopharmaceuticals (NGM) Reports Q2 Loss, Misses Revenue Estimates
NGM
Zacks Investment Research03 August 2023

NGM Biopharmaceuticals (NGM) came out with a quarterly loss of $0.46 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.59 per share a year ago.

NGM Bio to Participate in Upcoming Investor Conferences
NGM Bio to Participate in Upcoming Investor Conferences
NGM Bio to Participate in Upcoming Investor Conferences
NGM
GlobeNewsWire25 May 2023

SOUTH SAN FRANCISCO, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at the following upcoming investor conferences.

FAQ

  • What is the primary business of NGM Biopharmaceuticals?
  • What is the ticker symbol for NGM Biopharmaceuticals?
  • Does NGM Biopharmaceuticals pay dividends?
  • What sector is NGM Biopharmaceuticals in?
  • What industry is NGM Biopharmaceuticals in?
  • What country is NGM Biopharmaceuticals based in?
  • When did NGM Biopharmaceuticals go public?
  • Is NGM Biopharmaceuticals in the S&P 500?
  • Is NGM Biopharmaceuticals in the NASDAQ 100?
  • Is NGM Biopharmaceuticals in the Dow Jones?
  • When was NGM Biopharmaceuticals's last earnings report?
  • When does NGM Biopharmaceuticals report earnings?
  • Should I buy NGM Biopharmaceuticals stock now?

What is the primary business of NGM Biopharmaceuticals?

NGM Biopharmaceuticals, Inc. is a biopharmaceutical company that works with clinical stages of diseases. They are involved in the development of new therapeutic agents for the treatment of cardiovascular-metabolic, liver, oncological, and ophthalmological diseases. NGM Biopharmaceuticals, Inc. was registered in 2007, and its headquarters are located in South San Francisco, California.

What is the ticker symbol for NGM Biopharmaceuticals?

The ticker symbol for NGM Biopharmaceuticals is NASDAQ:NGM

Does NGM Biopharmaceuticals pay dividends?

No, NGM Biopharmaceuticals does not pay dividends

What sector is NGM Biopharmaceuticals in?

NGM Biopharmaceuticals is in the Healthcare sector

What industry is NGM Biopharmaceuticals in?

NGM Biopharmaceuticals is in the Biotechnology industry

What country is NGM Biopharmaceuticals based in?

NGM Biopharmaceuticals is headquartered in United States

When did NGM Biopharmaceuticals go public?

NGM Biopharmaceuticals's initial public offering (IPO) was on 04 April 2019

Is NGM Biopharmaceuticals in the S&P 500?

No, NGM Biopharmaceuticals is not included in the S&P 500 index

Is NGM Biopharmaceuticals in the NASDAQ 100?

No, NGM Biopharmaceuticals is not included in the NASDAQ 100 index

Is NGM Biopharmaceuticals in the Dow Jones?

No, NGM Biopharmaceuticals is not included in the Dow Jones index

When was NGM Biopharmaceuticals's last earnings report?

NGM Biopharmaceuticals's most recent earnings report was on 3 May 2024

When does NGM Biopharmaceuticals report earnings?

The date for NGM Biopharmaceuticals's next earnings report has not been announced yet

Should I buy NGM Biopharmaceuticals stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions